{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:55Z","timestamp":1783850215179,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03031-4","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:54:04Z","timestamp":1732276444000},"page":"442-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia\u00a0A Without Inhibitors"],"prefix":"10.1007","volume":"42","author":[{"given":"Mar\u00eda Teresa","family":"\u00c1lvarez Rom\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-4479","authenticated-orcid":false,"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Margas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Wdowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Santagostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"3031_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/2040620717746312","volume":"9","author":"P Balkaransingh","year":"2018","unstructured":"Balkaransingh P, Young G. Novel therapies and current clinical progress in hemophilia\u00a0A. Ther Adv Hematol. 2018;9:49\u201361.","journal-title":"Ther Adv Hematol"},{"key":"3031_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","volume":"8","author":"K Lieuw","year":"2017","unstructured":"Lieuw K. Many factor\u00a0VIII products available in the treatment of hemophilia\u00a0A: an embarrassment of riches? J Blood Med. 2017;8:67\u201373.","journal-title":"J Blood Med"},{"issue":"Suppl 6","key":"3031_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of haemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"key":"3031_CR4","unstructured":"United States Food & Drug Administration. HEMLIBRA Full Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf. Accessed July 2024."},{"key":"3031_CR5","unstructured":"European Medicines Agency. HEMLIBRA Summary of Product Characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf. Accessed July 2024."},{"key":"3031_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12571","volume":"5","author":"BB Warren","year":"2021","unstructured":"Warren BB, Chan A, Manco-Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia\u00a0A with and without inhibitors: a single-center report. Res Pract Thromb Haemost. 2021;5:e12571.","journal-title":"Res Pract Thromb Haemost"},{"key":"3031_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","volume":"383","author":"BA Konkle","year":"2020","unstructured":"Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor\u00a0VIII replacement therapy for hemophilia\u00a0A. N Engl J Med. 2020;383:1018\u201327.","journal-title":"N Engl J Med"},{"key":"3031_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/bloodadvances.2021006119","volume":"6","author":"T Lissitchkov","year":"2022","unstructured":"Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia\u00a0A: results from a phase\u00a01 repeat-dose study. Blood Adv. 2022;6:1089\u201394.","journal-title":"Blood Adv"},{"key":"3031_CR9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.2019001292","volume":"135","author":"E Seth Chhabra","year":"2020","unstructured":"Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor\u00a0VIII replacement for hemophilia\u00a0A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135:1484\u201396.","journal-title":"Blood"},{"key":"3031_CR10","unstructured":"United States Food & Drug Administration. ALTUVIIIO Highlights of Prescribing Information. 2024. https:\/\/products.sanofi.us\/altuviiio\/altuviiio.pdf. Accessed July 2024"},{"issue":"Suppl. 2","key":"3031_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100288","volume":"7","author":"L Malec","year":"2023","unstructured":"Malec L, Peyvandi F, Chan AKC, et al. Efanesoctocog alfa prophylaxis for previously treated patients <12 years of age with severe hemophilia\u00a0A (LB 01.1). Res Pract Thromb Haemost. 2023;7(Suppl. 2): 100288.","journal-title":"Res Pract Thromb Haemost"},{"key":"3031_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia\u00a0A. N Engl J Med. 2023;388:310\u20138.","journal-title":"N Engl J Med"},{"key":"3031_CR13","unstructured":"Sobi. EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia\u00a0A (Press Release). 2023. https:\/\/www.sobi.com\/en\/press-releases\/ema-validates-marketing-authorisation-application-efanesoctocog-alfa-treatment-haemophilia-2128255. Accessed July 2024"},{"key":"3031_CR14","unstructured":"European Medicines Agency. Altuvoct - Summary of opinion. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-altuvoct_en.pdf. Accessed July 2024"},{"key":"3031_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"issue":"Suppl. 2","key":"3031_CR16","first-page":"680","volume":"7","author":"A Tosetto","year":"2023","unstructured":"Tosetto A, Arnaud A, Kragh N, et al. Efanesoctocog alfa vs standard half-life (Octocog alfa) FVIII therapies for prophylaxis in adolescents and adults with severe hemophilia\u00a0A\u202f: a matching-adjusted indirect comparison and meta-analysis (PB0213). Res Pract Thromb Haemost. 2023;7(Suppl. 2):680.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl. 2","key":"3031_CR17","first-page":"688","volume":"7","author":"R Klamroth","year":"2023","unstructured":"Klamroth R, Guyot P, Arnaud A, et al. Efanesoctocog alfa versus extended half-life factor\u00a0VIII therapies for prophylaxis in adolescents and adults with severe hemophilia\u00a0A: a matching-adjusted indirect comparison and meta-analysis (PB0201). Res Pract Thromb Haemost. 2023;7(Suppl. 2):688.","journal-title":"Res Pract Thromb Haemost"},{"key":"3031_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia\u00a0A without inhibitors. N Engl J Med. 2018;379:811\u201322.","journal-title":"N Engl J Med"},{"key":"3031_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2019-123689","volume":"134","author":"A Kiialainen","year":"2019","unstructured":"Kiialainen A, Niggli M, Kempton CL, et al. Bone and joint health markers in persons with hemophilia\u00a0A (PwHA) treated with emicizumab in HAVEN\u00a03. Blood. 2019;134:626.","journal-title":"Blood"},{"key":"3031_CR20","first-page":"136","volume":"29","author":"A Weyand","year":"2023","unstructured":"Weyand A, Meunier S, Amano K, et al. PO202 Treatment of bleeding episodes with efanesoctocog alfa in patients with severe haemophilia\u00a0A in the phase\u00a03 XTEND-1 study. Haemophilia. 2023;29:136.","journal-title":"Haemophilia"},{"key":"3031_CR21","unstructured":"Phillippo DM, Ades A, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Report by the Decision Support Unit. 2016. https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-forpopulation-adj. Accessed July 2024"},{"key":"3031_CR22","unstructured":"Papanicolaou A. Taylor Approximation and the Delta Method. 2009. https:\/\/www.stat.rice.edu\/~dobelman\/notes_papers\/math\/TaylorAppDeltaMethod.pdf. Accessed July 2024"},{"key":"3031_CR23","unstructured":"R Core Team. A language and environment for statistical computing. 2023. https:\/\/www.R-project.org\/. Accessed July 2024"},{"key":"3031_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100176","volume":"7","author":"T Lissitchkov","year":"2023","unstructured":"Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S. Pharmacokinetics of recombinant factor\u00a0VIII in adults with severe hemophilia\u00a0A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. Res Pract Thromb Haemost. 2023;7: 100176.","journal-title":"Res Pract Thromb Haemost"},{"key":"3031_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1182\/blood.2023021832","volume":"143","author":"SW Pipe","year":"2024","unstructured":"Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia\u00a0A (HAVEN 7): primary analysis of a phase\u00a03b open-label trial. Blood. 2024;143:1355\u201364.","journal-title":"Blood"},{"key":"3031_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200\u201311.","journal-title":"Med Decis Making"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03031-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:02:41Z","timestamp":1738234961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03031-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03031-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alix Arnaud, Amanda Wilson, and Patricia Guyot are Sanofi employees and may hold stock\/stock options in Sanofi. Nana Kragh and Elena Santagostino are employees of Sobi and may hold stock\/stock options in Sobi. Marlena Wdowiak and Wojciech Margas are employees of Putnam PHMR. Piotr Wojciechowski is a co-founder of Assignity and an external consultant at Putnam PHMR. Mar\u00eda Teresa \u00c1lvarez Rom\u00e1n has received reimbursement for attending symposia\/congresses and\/or honoraria for speaking and\/or honoraria for consulting, and\/or funds for research from Takeda, Bayer, CSL-Behring, Novo Nordisk, Sobi, Roche, Biomarin, Novartis, Amgen, and Pfizer.\u00a0Piotr Wojciechowski\u2019s and Wojciech Margas\u2019 affiliation Assignity is now called Clever-Access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is a post hoc analysis and modelling of data already collected and\/or published data. Original studies were all approved by the relevant institutional review boards at each study site and were carried out in accordance with the International Conference on Harmonisation good clinical practice guidelines and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}